Press Release

Proteon Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference December 9th

December 2, 2015 at 8:00 AM EST

WALTHAM, Mass., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced today that Company management will present at the Oppenheimer 26th Annual Healthcare Conference in New York City on Wednesday, December 9, 2015 at 9:45 am ET.

A live audio webcast of the presentation can be accessed by visiting the Investor and Media section of the Company's website at A replay of the webcast will be archived on the Proteon website following the presentation.

About Proteon Therapeutics

Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug intended to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Proteon is currently evaluating vonapanitase in two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic AVF for hemodialysis and has completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). For more information, please visit

Investor Contact 
George Eldridge, Senior Vice President and Chief Financial Officer

Press Contact
Chris Erdman, MacDougall Biomedical Communications

Proteon logo

Proteon Therapeutics Inc.